<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210501051142N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-28</date_registration>
      <primary_sponsor>Islamic Azad University, Khomein branch</primary_sponsor>
      <public_title>Comparison of the effect of violet flower and evening primrose flower on the anxiety</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of violet flower and evening primrose flower on the anxiety of menopausal women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68482</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Menopausal women are assigned to two intervention groups and one control group based on the randomization sequence that will be generated in advance, which is unpredictable and its arrangement is completely random. To allocate the samples, the block randomization method with the size of 3 and 6 blocks will be used, so that by using the software for generating random numbers in the block method, a randomization sequence will be generated according to the sample size required for the three groups. First, all the modes in which the 3 letters A, B and C can be put together in blocks of 3 and 6 are generated, then a block is randomly selected by placing it among the blocks and the layout pattern in that block will be used to allocate women. Finally this block will be placed in the main container and another block will be selected again. Blocks of 3 and 6 will all be in the same container. All this will be done with software called Sealed Envelope. With this method, concealment will also be observed. The concept of concealment is to unpredictably assign individuals to groups that the researcher will not be able to predict which group the next person will be in, Blinding description: The data analyzer will not know how the samples are placed in the intervention and control groups. Other people in the study will be aware of this placement.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In the first intervention group (violet flower syrup), women will consume 5 ml of violet flower syrup twice a day (in the morning after waking up and at night before going to bed) for one month. At the beginning and end of the study, the Spielberger questionnaire, and the depression, anxiety and stress scale-21 form are completed by the menopausal women of all three groups, and their anxiety level is determined based on this. Intervention 2: Intervention group 2: In the second intervention group (evening primrose flower), postmenopausal women will consume 1 gram of evening primrose flower syrup twice a day (once in the morning and once at night with a glass of water) for one month. At the beginning and end of the study, the Spielberger questionnaire, and the depression, anxiety and stress scale-21 form are completed by the menopausal women of all three groups, and their anxiety level is determined based on this. Intervention 3: Control group: In this period, they do not receive this intervention and only fill the Spielberger questionnaire and the depression, anxiety and stress-21 scale form at the beginning and end of the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only the part of the data related to the original outcome will be able to be shared.

When:
since the spring of 2023

To whom:
Researchers and students in this field

Conditions:
In order to reduce the anxiety level of menopausal women

Where to obtain:
Vice chancellor for education and research, Khomein Azad university

How to obtain:
These documents will be available on the website of Khomein Azad university.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zeynab Beheshti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University campus, Daneshgah Blvd., Khomein</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۸۸۱۶۱۳۴۸۵</zip>
        <telephone>+98 86 4633 7801</telephone>
        <email>golmehrsherafati@gmail.com</email>
        <affiliation>Islamic Azad University, Khomein branch</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zeynab Beheshti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University campus, Daneshgah Blvd., Khomein</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۸۸۱۶۱۳۴۸۵</zip>
        <telephone>+98 86 4633 7801</telephone>
        <email>golmehrsherafati@gmail.com</email>
        <affiliation>Islamic Azad University, Khomein branch</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in the study
Having at least reading and writing literacy
Menopause (at least 12 months of spontaneous cessation of menstruation)
Age 40-65 years</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Preventing the patient from taking herbal medicines
Being admitted to the hospital
The occurrence of a severe stressful event before entering the intervention (death of relatives, separation from spouse, sick person in the family, dismissal and bankruptcy)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F06.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anxiety disorder due to known physiological condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In the first intervention group (violet flower syrup), women will consume 5 ml of violet flower syrup twice a day (in the morning after waking up and at night before going to bed) for one month. At the beginning and end of the study, the Spielberger questionnaire, and the depression, anxiety and stress scale-21 form are completed by the menopausal women of all three groups, and their anxiety level is determined based on this.</i_keyword>
      <i_keyword>Intervention group 2: In the second intervention group (evening primrose flower), postmenopausal women will consume 1 gram of evening primrose flower syrup twice a day (once in the morning and once at night with a glass of water) for one month. At the beginning and end of the study, the Spielberger questionnaire, and the depression, anxiety and stress scale-21 form are completed by the menopausal women of all three groups, and their anxiety level is determined based on this.</i_keyword>
      <i_keyword>Control group: In this period, they do not receive this intervention and only fill the Spielberger questionnaire and the depression, anxiety and stress-21 scale form at the beginning and end of the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety rate. Timepoint: Before the intervention and twice after the start of the first intervention (on the 15th and 30th days of the intervention), the level of anxiety of each patient is measured. Method of measurement: At the beginning and end of the study, the demographic questionnaire, the Spielberger questionnaire, and the depression, anxiety and stress scale-21 form are completed by the menopausal women of all three groups, and their anxiety level is determined based on this.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University, Khomein branch</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-22</approval_date>
        <contact_name>Ethics committee of faculty of medical sciences, Aligudarz Azad university</contact_name>
        <contact_address>Daneshgah square, Velayat Blvd., Aligudarz, Lorestan province Aligudarz Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
